Navigation Links
MedMira Strengthens North American Sales Channels, Adding VWR as Distributor for the United States
Date:5/28/2009

HALIFAX, May 28 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, announced today that VWR International, LLC (VWR) has joined the Company's U.S. distribution network. Headquartered in West Chester, Pennsylvania, VWR is a global laboratory supply and distribution company with worldwide sales in excess of $3.7 billion.

"The U.S. is an important market for MedMira and building out our distribution network is a key initiative in maintaining and expanding our market position. Adding VWR to our U.S. distribution network will increase our sales revenues and enable us to fully capitalize on opportunities to launch new products in the market," said Hermes Chan, CEO, MedMira. "VWR will work with MedMira's U.S.-based sales and marketing partner American Health Diagnostics (AHD) to expand sales for our Reveal G3 rapid HIV test and identify opportunities for new MedMira products."

"We provide our customers with the most innovative products available on the market today. Adding MedMira's 3-minute rapid HIV test to our product portfolio will provide our U.S. customers with a critical diagnostic tool," said Mark McLoughlin, Senior Vice President, Category Management North America, VWR.

About MedMira

MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this statement.


'/>"/>
SOURCE MEDMIRA INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medpace Strengthens Presence in Central Europe
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
5. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
6. Anavex strengthens Board of Directors
7. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
8. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
9. JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
10. BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
11. Hcareers.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) ... December 31, 2015. --> --> ... net loss of $29.3 million, or $0.34 loss per share, compared ... share for the same period in 2014. For the year ended ... million, or $1.05 loss per share, as compared to a net ...
(Date:2/11/2016)...  Bioethics International, a not-for-profit organization focused on the ethics ... made accessible to patients around the world, today announced that ... publication of the Good Pharma Scorecard an ... as one of BMJ Open ,s ,Most Popular Articles, ... most frequently read. Ed Sucksmith , assistant editor ...
(Date:2/11/2016)... NY (PRWEB) , ... February ... ... a business-to-business publication dedicated to delivering cutting-edge information focused on the development ... Life Sciences to become a premier sponsor of the 2016 BioProcess International ...
(Date:2/11/2016)... 2016   BioInformant announces the February 2016 ... Products, Opportunities, Tools, and Technologies – Market Size, Segments, ... The first and only ... industry, BioInformant has more than a decade of historical ... by stem cell type. This powerful 175 page global ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):